{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-022760","form_type":"8-K","ticker":"CDT","cik":"0001896212","company_name":"CDT Equity Inc.","filed_at":"2025-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.541349+00:00","generated_at":"2026-05-17T16:49:26.521247+00:00","sec_items":["5.02","5.03","5.07","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Conduit renames to CDT Equity Inc., appoints James Bligh permanent CFO, adds 2M shares to incentive plan","bullets":["Name change from Conduit Pharmaceuticals Inc. to CDT Equity Inc. effective Aug 5, 2025; ticker remains CDT; no shareholder vote required.","James Bligh, co-founder and interim CFO since May 2024, appointed permanent CFO; compensation unchanged; retains board seat.","Stockholders approved amendment to 2023 Stock Incentive Plan adding 2,000,000 authorized shares for awards.","Press release details strategic shift: AI-driven drug repurposing via Sarborg partnership, animal health collaboration with Manoira, and evaluation of cryptocurrency treasury reserve strategy.","All five director nominees elected: Andrew Regan, Freda Lewis-Hall, James Bligh, Chele Chiavacci Farley, Simon Fry; auditor CBIZ CPAs P.C. ratified."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-022760","json":"https://secwatch.observer/filing/0001641172-25-022760.json","markdown":"https://secwatch.observer/filing/0001641172-25-022760.md","text":"https://secwatch.observer/filing/0001641172-25-022760.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1896212/000164117225022760/0001641172-25-022760-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1896212/000164117225022760/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T16:49:26.521247+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b2718b80c681914b5cafdd6046a29c9712260565","claim":"CDT Equity Inc.: Amended certificate of incorporation to change company name from Conduit Pharmaceuticals Inc. to CDT Equity Inc (effective 2025-08-05).","evidence_excerpt":"On August 5, 2025, the Company filed an amendment to its Second Amended and Restated Certificate of Incorporation (the “ Certificate of Incorporation ”), to effect a change of the Company’s name from “Conduit Pharmaceuticals Inc.” to “CDT Equity Inc.” (the “ Name Change ”), which became effective at 5 p.m. Eastern Time on August 5, 2025.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1896212/000164117225022760/0001641172-25-022760-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2025-08-05"}],"fact_type":"governance_change"},{"claim_id":"bcf024fcf2ca79ca96e1f6a8367328b8c8c92349","claim":"CDT Equity Inc.: Amended and restated bylaws to reflect name change and update quorum description per a prior amendment (effective 2025-08-05).","evidence_excerpt":"In connection with the Name Change, the Company also amended and restated its Amended and Restated Bylaws (as amended, the “ Second Amended and Restated Bylaws ”) on August 5, 2025 to reflect the Name Change.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1896212/000164117225022760/0001641172-25-022760-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2025-08-05"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}